These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 33991137)

  • 1. An updated review on the effects of depot medroxyprogesterone acetate on the mucosal biology of the female genital tract.
    Ayele H; Perner M; McKinnon LR; Birse K; Farr Zuend C; Burgener A
    Am J Reprod Immunol; 2021 Sep; 86(3):e13455. PubMed ID: 33991137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genital Injury Signatures and Microbiome Alterations Associated With Depot Medroxyprogesterone Acetate Usage and Intravaginal Drying Practices.
    Birse KD; Romas LM; Guthrie BL; Nilsson P; Bosire R; Kiarie J; Farquhar C; Broliden K; Burgener AD
    J Infect Dis; 2017 Feb; 215(4):590-598. PubMed ID: 28011908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medroxyprogesterone acetate and levonorgestrel increase genital mucosal permeability and enhance susceptibility to genital herpes simplex virus type 2 infection.
    Quispe Calla NE; Vicetti Miguel RD; Boyaka PN; Hall-Stoodley L; Kaur B; Trout W; Pavelko SD; Cherpes TL
    Mucosal Immunol; 2016 Nov; 9(6):1571-1583. PubMed ID: 27007679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Depot-medroxyprogesterone acetate reduces genital cell-cell adhesion molecule expression and increases genital herpes simplex virus type 2 infection susceptibility in a dose-dependent fashion.
    Quispe Calla NE; Vicetti Miguel RD; Aceves KM; Torres A; Cherpes TL
    Contraception; 2019 Nov; 100(5):397-401. PubMed ID: 31302121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human vaginal histology in long-term users of the injectable contraceptive depot-medroxyprogesterone acetate.
    Bahamondes MV; Castro S; Marchi NM; Marcovici M; Andrade LA; Fernandes A; Bahamondes L
    Contraception; 2014 Aug; 90(2):117-22. PubMed ID: 24613369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progestin-based contraception regimens modulate expression of putative HIV risk factors in the vaginal epithelium of pig-tailed Macaques.
    Bosinger SE; Tharp GK; Patel NB; Zhao C; Payne TL; Dietz Ostergaard S; Butler K; Ellis S; Johnson RL; Kersh EN; McNicholl JM; Vishwanathan SA
    Am J Reprod Immunol; 2018 Oct; 80(4):e13029. PubMed ID: 30076667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of progestin-based contraceptives on HIV-associated vaginal immune biomarkers and microbiome in adolescent girls.
    Nasr MA; Aldous A; Daniels J; Joy C; Capozzi E; Yang M; Moriarty P; Emmanuel-Baker V; Malcolm S; Green SJ; Gomez-Lobo V; Ghosh M
    PLoS One; 2024; 19(7):e0306237. PubMed ID: 39008499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential effects of depot medroxyprogesterone acetate administration on vaginal microbiome in Hispanic White and Black women.
    Yang L; Hao Y; Hu J; Kelly D; Li H; Brown S; Tasker C; Roche NE; Chang TL; Pei Z
    Emerg Microbes Infect; 2019; 8(1):197-210. PubMed ID: 30866773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term effect of depot medroxyprogesterone acetate on vaginal microbiota, epithelial thickness and HIV target cells.
    Mitchell CM; McLemore L; Westerberg K; Astronomo R; Smythe K; Gardella C; Mack M; Magaret A; Patton D; Agnew K; McElrath MJ; Hladik F; Eschenbach D
    J Infect Dis; 2014 Aug; 210(4):651-5. PubMed ID: 24652495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on the Impact of Depot Medroxyprogesterone Acetate on Vaginal Mucosal Endpoints and Relevance to Sexually Transmitted Infections.
    Dabee S; Balle C; Onono M; Innes S; Nair G; Palanee-Phillips T; Burgener AD; Bosinger SE; Passmore JS; Heffron R; Jaspan H; Happel AU
    Curr HIV/AIDS Rep; 2023 Aug; 20(4):251-260. PubMed ID: 37341916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased Cervical CD4
    Lajoie J; Tjernlund A; Omollo K; Edfeldt G; Röhl M; Boily-Larouche G; Cheruiyot J; Kimani M; Kimani J; Oyugi J; Broliden K; Fowke KR
    AIDS Res Hum Retroviruses; 2019 Mar; 35(3):236-246. PubMed ID: 30585733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of Hormonal Contraceptive Use and HIV on Cervicovaginal Cytokines and Microbiota in Malawi.
    Haddad LB; Tang JH; Davis NL; Kourtis AP; Chinula L; Msika A; Tegha G; Hosseinipour MC; Nelson JAE; Hobbs MM; Gajer P; Ravel J; De Paris K
    mSphere; 2023 Feb; 8(1):e0058522. PubMed ID: 36622252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Depot medroxyprogesterone acetate increases immune cell numbers and activation markers in human vaginal mucosal tissues.
    Chandra N; Thurman AR; Anderson S; Cunningham TD; Yousefieh N; Mauck C; Doncel GF
    AIDS Res Hum Retroviruses; 2013 Mar; 29(3):592-601. PubMed ID: 23189932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initiating Intramuscular Depot Medroxyprogesterone Acetate Increases Frequencies of Th17-like Human Immunodeficiency Virus Target Cells in the Genital Tract of Women in South Africa: A Randomized Trial.
    Bunjun R; Ramla TF; Jaumdally SZ; Noël-Romas L; Ayele H; Brown BP; Gamieldien H; Harryparsad R; Dabee S; Nair G; Onono M; Palanee-Phillips T; Scoville CW; Heller KB; Baeten JM; Bosinger SE; Burgener A; Passmore JS; Jaspan H; Heffron R
    Clin Infect Dis; 2022 Nov; 75(11):2000-2011. PubMed ID: 35941737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal post-menopausal women.
    Orr-Walker BJ; Evans MC; Ames RW; Clearwater JM; Cundy T; Reid IR
    Clin Endocrinol (Oxf); 1998 Nov; 49(5):615-8. PubMed ID: 10197077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The contraceptive use of depot medroxyprogesterone acetate.
    Hickey M; Fraser I
    Clin Obstet Gynecol; 1995 Dec; 38(4):849-58. PubMed ID: 8616981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term effects of depot-medroxyprogesterone acetate on lipoprotein metabolism.
    Garza-Flores J; De la Cruz DL; Valles de Bourges V; Sanchez-Nuncio R; Martinez M; Fuziwara JL; Pérez-Palacios G
    Contraception; 1991 Jul; 44(1):61-71. PubMed ID: 1832626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot.
    Handelsman DJ; Conway AJ; Howe CJ; Turner L; Mackey MA
    J Clin Endocrinol Metab; 1996 Nov; 81(11):4113-21. PubMed ID: 8923869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Depot medroxyprogesterone acetate (DMPA) enhances susceptibility and increases the window of vulnerability to HIV-1 in humanized mice.
    Wessels JM; Nguyen PV; Vitali D; Mueller K; Vahedi F; Felker AM; Dupont HA; Bagri P; Verschoor CP; Deshiere A; Mazzulli T; Tremblay MJ; Ashkar AA; Kaushic C
    Sci Rep; 2021 Feb; 11(1):3894. PubMed ID: 33594113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of Cyclofem in the treatment of depot medroxyprogesterone acetate induced amenorrhea.
    Piya-Anant M; Koetsawang S; Patrasupapong N; Dinchuen P; d'Arcangues C; Piaggio G; Pinol A
    Contraception; 1998 Jan; 57(1):23-8. PubMed ID: 9554247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.